TABLE 2.
Univariate analyses of progression‐free survival among PTC patients in the training cohort
| Variables | Progression‐free survival | ||
|---|---|---|---|
| HR | 95%CI | p | |
| Age (year) | |||
| ≤57 | 1.000 | ||
| >57 | 3.412 | (1.624, 7.717) | 0.001* |
| Stromal score | |||
| ≤−677.0 | 1.000 | ||
| >−677 | 0.302 | (0.140, 0.655) | 0.002* |
| Sex | |||
| Female | 1.000 | ||
| Male | 1.530 | (0.706, 3.319) | 0.282 |
| Race | |||
| White | 1.000 | ||
| Black | 0.537 | (0.072, 3.986) | 0.543 |
| Other | 1.212 | (0.362, 4.054) | 0.755 |
| Radiation therapy | |||
| No | 1.000 | ||
| Yes | 1.738 | (0.765, 3.947) | 0.187 |
| Histological type | |||
| CPTC | 1.000 | ||
| FVPTC | 0.758 | (0.226, 2.543) | 0.653 |
| TCPTC | 1.777 | (0.609, 5.187) | 0.293 |
| Other | <0.001 | (<0.001, <0.001) | 0.997 |
| AJCC TNM stage | |||
| Stage I | 1.000 | ||
| Stage II | 1.089 | (0.205, 4.029) | 0.912 |
| Stage III | 1.618 | (1.061, 5.099) | 0.301 |
| Stage IV | 4.784 | (1.313, 9.117) | 0.001* |
| T status | |||
| T1 | 1.000 | ||
| T2 | 2.622 | (0.545, 12.630) | 0.229 |
| T3 | 5.474 | (1.251, 23.950) | 0.024* |
| T4 | 11.508 | (2.103, 62.960) | 0.005* |
| N status | |||
| N0 | 1.000 | ||
| N1 | 2.138 | (0.967, 4.728) | 0.061 |
| NX | 0.903 | (<0.001, <0.001) | 0.996 |
| M status | |||
| M0 | 1.000 | ||
| M1 | 9.386 | (2.139, 41.179) | 0.003* |
| MX | 1.510 | (0.692, 3.295) | 0.301 |
Abbreviations: AJCC TNM, American Joint Committee on Cancer Tumor Node Metastasis; CI, confidence interval; CPTC, classical PTC; FVPTC, follicular variant PTC; HR, hazard ratio; M, Metastasis; MX, metastasis cannot be measured; N, Node; NX, cancer in nearby lymph nodes cannot be measured; PTC, papillary thyroid carcinoma; T, Tumor; TCPTC, tall cell PTC.
*
p < 0.05.